RemedyMD`s Solution Addresses Institute of Medicine`s Top 100 Priorities and
Shifts Focus towards Research Based on More Comprehensive Scientific Evidence
SALT LAKE CITY--(Business Wire)--
RemedyMD (www.RemedyMD.com), the leading provider of Patient registry software,
today announced the first nationwide Type 2 Diabetes registry to help clinicians
and researchers identify which interventions are most appropriate for specific
patient populations.
Details about the registry: www.remedymd.com/cer100/type2.html
Aligned with the Institute of Medicine`s Top 100 Priorities for Comparative
Effectiveness Research (CER), RemedyMD`s type 2 diabetes registry includes
long-term cost and compares medical management with education, support groups
and behavior modification.
The type 2 diabetes registry includes all of the applications, data
infrastructure, and tools that clinicians and researchers need to gather,
synthesize and analyze both phenotypic and genotypic data simultaneously.
"Our experience has shown when you view and report across all data types at the
same time, you discover patterns and associations that are indistinguishable
using traditional methodologies," said Gary D. Kennedy, Founder and CEO of
RemedyMD.
RemedyMD`s new type 2 diabetes registry includes a comprehensive set of
electronic data collection (EDC) forms that are specific to type 2 diabetes
research, ad hoc reporting capability, and pattern recognition tools that assist
users in identifying the most effective treatment options.
In support of this initiative RemedyMD is seeking additional partners who have
existing data that addresses the specific needs of type2 diabetes researchers.
All institutions involved in comparative effectiveness research that are
planning on submitting grant proposals for AHRQ funding are invited to visit:
www.remedymd.com/cer100/type2.html.
RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research:
www.remedymd.com/cer_kit.html
Ways to leverage type 2 diabetes registry: www.remedymd.com/CER100/type2.html
Comparative Effectiveness Research: www.remedymd.com/cer_home.html
Disease Registry Software: www.remedymd.com/registries_home.html
Institute of Medicine`s Top 100 Priorities for CER:
www.remedymd.com/cer_kit.html
About RemedyMD
RemedyMD is the leading provider of specialized software applications, tools,
and data necessary for comparative effectiveness research with more than 100
pre-built clinical, patient, and disease registry software applications.
RemedyMD solutions are personalized to the institution, the clinical specialty,
and to the individual provider`s preferences enabling researchers to identify
new patterns, facilitate new discoveries, and improve medical outcomes. For more
information, visit www.RemedyMD.com.
RemedyMD
Lane Peterson, 801-733-3383
lpeterson@remedymd.com
Copyright Business Wire 2009
